NRX Pharmaceuticals, Inc. (NRXP)

Over the past six months, several events have impacted NRX Pharmaceuticals' stock price. NRx Pharmaceuticals announced FDA Labeling Alignment for its Preservative-Free Ketamine Application on April 6, 2026. Hope Therapeutics announced a strategic partnership with Emobot to integrate its AI-powered "Depression Thermometer" on March 30, 2026. The company reported its Full-Year 2025 Results on March 24, 2026, highlighting a year-over-year reduction in operating expenses, $7.8 million cash on hand, and the conversion of all previously issued convertible debt into common stock by December 31, 2025. NRx Pharmaceuticals announced it would report its Full Year 2025 Financial Results and provide a Corporate Update on March 24, 2026 on March 19, 2026. The company announced an FDA Bioequivalence Determination by the Office of Generic Drugs for its Preservative-Free Ketamine Application on March 17, 2026. The CEO presented at NobleCon21 on December 3, 2025, providing a company update. NRx Pharmaceuticals and HOPE Therapeutics hosted a Corporate Update Call on December 2, 2025. The company held its Q3 2025 Financial Results Conference Call on November 17, 2025. In November 2024, NRXP achieved debt-free status and the FDA accepted the Abbreviated New Drug Application (ANDA) for KETAFREE.

Information regarding specific demand seasonality for NRX Pharmaceuticals, Inc.'s products and services is not explicitly available. Demand is likely driven by factors such as disease prevalence, treatment efficacy, regulatory approvals, and market access, rather than typical seasonal patterns.

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company is dedicated to addressing conditions characterized by suicidal ideation and treatment resistance, pursuing biopharmaceutical development and clinical delivery through HOPE Therapeutics, Inc. Its major product candidates include NRX-100 (preservative-free intravenous ketamine formulation) for suicidal ideation in patients with depression, and NRX-101 (oral fixed-dose combination of D-cycloserine and lurasidone) for suicidal treatment-resistant bipolar depression and chronic pain. HOPE Therapeutics, Inc. is establishing a network of interventional psychiatry clinics offering neuroplastic treatments.

NRX Pharmaceuticals, Inc. is headquartered in Wilmington, Delaware. Its clinical operations, through HOPE Therapeutics, Inc., are focused on establishing a nationwide network of interventional psychiatry clinics across the United States, aiming for driving-distance U.S. access by the end of 2026, utilizing over 400 Apollo TMS devices and approximately 20 U.S. clinics. The company has partnered with neurocare Group AG to create this national network of clinics.

NRX Pharmaceuticals' brand reputation has been positively influenced by FDA designations like Fast Track for NRX-100 and Breakthrough Therapy for NRX-101. Favorable bioequivalence determinations and labeling alignment from the FDA for its preservative-free ketamine application, along with anticipated FDA approvals in Q3 2026, contribute to a positive perception. Reduced operating expenses, a healthy cash balance, and the conversion of debt signal improved financial health. Strategic partnerships, like the one with Emobot, demonstrate a commitment to innovative healthcare delivery. Analyst expectations of profitability in 2026 further bolster its reputation.

NRX Pharmaceuticals, Inc. has a diverse ownership structure. Institutional investors hold approximately 11.26% to 17.41% of the company's stock, with major holders including Anson Funds Management LP and Vanguard Group Inc. Individual investors own approximately 70.75% of the stock, with Chaim Hurvitz owning the most shares. Insiders hold approximately 11.84% of the company's stock.